Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium

References

• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–43.10.1200/JCO.2010.30.1382
   PubMed Web of Science ®Google Scholar
• Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 2015;26(11):1627–42.10.1007/s10552-015-0657-6
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010;116:5568–74.10.1002/cncr.v116:24
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica. 2010;95(4):589–96.10.3324/haematol.2009.014274
   PubMed Web of Science ®Google Scholar
• O’Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113:3186–91.10.1002/cncr.v113:11
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl_5):v69–v82.
   PubMed Web of Science ®Google Scholar
• Alvarnas J, Brown P, Aoun P, Ballen KK, Barta SK, Bellam N, et al. NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia. Version 1. 2014.
   Google Scholar
• Gökbuget N. Recommendations of the European working group for adult ALL. Bremen: UNI-MED; 2011.
   Google Scholar
• Camera A, Annino L, Chiurazzi F, Fazi P, Cascavilla N, Fabbiano F, et al. GIMEMA ALL – rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica. 2004;89(2):145–53.
   PubMed Web of Science ®Google Scholar
• Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, Jakubas B, Palynyczko G, Lewandowski K, et al. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Ann Hematol. 2006;85(10):717–22.10.1007/s00277-006-0121-5
   PubMed Web of Science ®Google Scholar
• De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, et al. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. Ann Hematol. 2014;93(12):2011–8.10.1007/s00277-014-2143-8
   PubMed Web of Science ®Google Scholar
• Technische cel/Celulle Technique. Available from: https://tct.fgov.be/webetct/etct-web/
   Google Scholar
• FPS Economy, Belgian statistics, Health Index. Available from: http://statbel.fgov.be/nl/modules/publications/statistiques/economie/prijzen_-_consumptieprijsindex_vanaf_1920_en_gezondheidsindex_vanaf_1994.jsp
   Google Scholar
• Gökbuget N, Dombret H, Ribera J-M, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524–33.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–41.10.1182/blood-2011-12-399287
   PubMed Web of Science ®Google Scholar
• Dombret H, Thomas X, Chevallier P, Nivot E, Reitan J, Barber B, et al. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review. J Med Econ. 2016;19(11):1034–9.
   PubMed Web of Science ®Google Scholar
• Kreuzer K, Stuhlmann R, Lebioda A, Reitan J, Barber B, Barlev A. Hospitalisations among adult patients with Phnegative B-precursor relapsed or refractory (R/R) acute lymphoblastic leukaemia (ALL) receiving chemotherapy in Germany: a retrospective chart review. Value Health. 2015;18:A443.10.1016/j.jval.2015.09.1096
   PubMed Web of Science ®Google Scholar
• Pagano L, Oberti M, Esposito B, Reitan J, Barlev A, Barber B, et al. Retrospective chart review of hospitalisations during chemotherapy for adult patients with Ph-negative B-precursor relapsed or refractory (R/R) acute lymphoblastic leukaemia (ALL) in Italy. Value Health. 2015;18:A443.10.1016/j.jval.2015.09.1094
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.10.1016/S1470-2045(14)71170-2
   PubMed Web of Science ®Google Scholar
• Topp MS, Stein A, Gökbuget N, Fielding A, Schuh A, Ribera JM, et al. Blinatumomab improved overall survival in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER). 2016. EHA abstract S149.
   Google Scholar
• Kantarjian HM, DeAngelo DJ, Advani AS, Liedtke M, Stock W, Gökbuget N, et al. Overall survival in relapsed/refractory B-cell acute lymphoblastic leukemia patients receiving inotuzumab ozogamicin vs standard care in the phase 3 INO-VATE study. 2016. EHA Abstract: LB2233.
   Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• NIHDI. Available from: http://www.riziv.be/homenl.htm
   Google Scholar